An observational study in Mitral Valve Disease, sponsored by French Cardiology Society. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by French Cardiology Society · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Mitral Valve Insufficiency with a site in France — 17 open to participants now, 21 under way, none of them phase 3. Mitral Valve Insufficiency · France.
Among the 42 studies in Mitral Valve Insufficiency with a site in France, this one is the 8th largest by planned enrollment of the 16 observational ones that give a count, is one of 5 that started in 2016, is one of 16 observational ones, reaches primary completion later than 8 of the 20 other live ones, and was the 17th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →17 of the 42 studies in Mitral Valve Insufficiency with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
4C Medical Technologies, Inc. · Sites in France, United States, Canada and 4 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Medtronic Cardiovascular · Sites in France, Denmark, Germany and 5 more countries
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in France, United States, Germany
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2016.
This study's planned enrollment of 500 is above the median of 159 across 170 observational studies indexed under Mitral Valve Insufficiency.
Median enrollment 57 across the 26 interventional studies, 470 across the 16 observational. Of the 12 that completed or were terminated, 5 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 42 have an industry lead sponsor. The 10 most frequent:
French Cardiology Society is the lead sponsor of 85 studies on the registry; 16 are open to participants now.
French Cardiology Society has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Mitral Valve Insufficiency with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03271762Nantes University HospitalMulticentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery | 2026-12 |
| NCT02925819French Cardiology SocietyManagement and Clinical Outcomes of Patients With Severe Mitral Valve Disease Not Suitable for Surgery | 2026-12 |
| NCT04029363HighLife SASExpanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk | 2026-12-15 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Mitral Valve Insufficiency with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to collect in a prospective registry all cases of French patients undergoing an assessment for percutaneous treatment of mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement. In these patients, valvular surgery should be considered contra-indicated or at prohibitive risk. This registry will evaluate the morbidity and mortality up to 24 months for those patients with severe mitral valve disease who are not included in a clinical trial. The association of demographic, clinical, laboratory, echocardiographic variables and treatment options with morbidity and mortality will be evaluated by univariate and multivariate analyses.
Patients with symptomatic severe mitral valve disease will have a medical evaluation visit (physical examination, ECG, biology) with transthoracic ± transesophageal echocardiography in each center. If the patient is considered not eligible for surgery by the heart-team and is not included in a clinical trial, the investigator informs the patient of the existence of the registry and verifies that it does not express opposition to the use of its clinical data.
In each participating center, demographic information, clinical, laboratory, echocardiographic and treatment options will be collected and reported in an electronic case report form (e-CRF). Each center will be responsible of patient monitoring, including phone call at 6 months and a medical visit at 1 and 2 years. Transthoracic echocardiography will also be performed at 1 year and 2 years.
French patients undergoing an assessment for percutaneous treatment of symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement with contra-indication to or prohibitive risk of surgery.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
All cause death and heart failure at 24 months
Death from any cause or unscheduled hospitalization for heart failure at 24 months
Time frame: 24 months of follow-up
Overall survival at 24 months
The survival rate will be determined between the date of inclusion in the cohort and the date of occurrence of death, whatever the cause.
Time frame: 24 months of follow-up
Survival without major cardiovascular event
The rate of survival without major cardiovascular event rate will be determined between the date of inclusion and date of occurrence of a major cardiovascular event (unscheduled rehospitalisation for heart failure, stroke, death of cardiovascular, myocardial infarction).
Time frame: 24 months of follow-up
Rate of unscheduled hospitalizations for heart failure
Rate of unscheduled hospitalizations for heart failure at 24 months.
Time frame: 24 months of follow-up
Functional evaluation
It will be defined by changes in NYHA functional class at 24 months.
Time frame: 24 months of follow-up
Early safety
Defined as absence of all-cause mortality, all stroke, severe bleeding, acute kidney injury stage 2 or 3, major vascular complication, and valve related dysfunction requiring repeat interventional transcatheter procedure or surgery.
Time frame: Until Hospital Discharge, up to 6 months
Plan to share: No
Started Oct 2016 (actual). Primary completion is estimated for Dec 2026, 122 months after the start.
Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 122 months is above that.
Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Cardiology Society